UBS AM
KLRS

UBS AM’s Kalaris Therapeutics KLRS Stock Holding History

UBS AM’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,029
Closed -$50.9K – 2611
2023
Q3 		$50.9K Hold
1,029
– – ﹤0.01% 2578
2023
Q2 		$93.2K Hold
1,029
– – ﹤0.01% 2646
2023
Q1 		$93.2K Buy
+1,029
New +$131K ﹤0.01% 2646
2022
Q4 		– Sell
-628
Closed -$114K – 2749
2022
Q3 		$114K Sell
628
-693
-52% -$108K ﹤0.01% 2673
2022
Q2 		$118K Hold
1,321
– – ﹤0.01% 2631
2022
Q1 		$205K Hold
1,321
– – ﹤0.01% 2673
2021
Q4 		$393K Buy
1,321
+142
+12% +$65.9K ﹤0.01% 2621
2021
Q3 		$680K Buy
1,179
+598
+103% +$277K ﹤0.01% 2349
2021
Q2 		$264K Buy
+581
New +$300K ﹤0.01% 2668

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

UBS AM's KLRS Position: Q4 2023 in Review

UBS AM sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 1,029 shares — an estimated $50.9K sold.

UBS AM first reported a position in KLRS in Q2 2021 and held it in 9 quarters. The position peaked at $680K in Q3 2021. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • UBS AM reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • UBS AM sold 1,029 Kalaris Therapeutics shares in Q4 2023, an estimated $50.9K.
  • UBS AM first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 9 quarters.
  • UBS AM's Kalaris Therapeutics position peaked at $680K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on UBS AM's 13F filing for Q4 2023, filed 14 Feb 2024.